Jeremy W. Jacobs

Jeremy W. Jacobs

Auto-generated profile, based on publicly available information

Jeremy W. Jacobs

Department of Pathology, Microbiology, and Immunology Vanderbilt University Nashville Tennessee USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2020 in Transfusion
Verified
Journal Article
Open access
PDF file
JJJeremy Jacobs
Jeremy Jacobs
QEQuentin Eichbaum
Quentin Eichbaum
Background: Autoimmune hemolytic anemia (AIHA) has many known disease associations, including autoimmune, lymphoproliferative, and certain infectious diseases, as well as various medications. Studies have found that severe cases of coronavirus disease 2019 (COVID‐19) may be associated with coagulopathies; however, the potential association with AIHA is not clear.Case Report: A patient with no known risk factors or underlying predisposition for developing AIHA presented to a hospital with vague symptoms and profound anemia with a complicated blood bank evaluation. She was found to have COVID‐19 and AIHA, for which extensive laboratory testing was performed, including direct antiglobulin tests, elution studies, and cold agglutinin titers, to identify the causative autoantibody. She required multiple blood transfusions and therapeutic interventions before clinical stabilization.Discussion: AIHA is a complex disease with a spectrum of presentations and clinical severity. Many diseases have been associated with a propensity for developing AIHA; however, there are few cases in the literature of patients with COVID‐19 and AIHA. Most of the reports involve patients with other underlying conditions that are known to be associated with the development of AIHA. The presentation, clinical findings, and therapeutic interventions in a patient with severe AIHA, without other underlying conditions, in the setting of COVID‐19 are discussed.Conclusions: There are few reports of patients with concurrent COVID‐19 and AIHA, and the association is not clear. Although COVID‐19 has been shown to be associated with coagulopathies, more research is required to determine whether AIHA may also be a potential complication.

17 December 2021 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
JJJeremy W Jacobs
Jeremy W Jacobs
GBGarrett S Booth
Garrett S Booth
Objectives: To summarize the epidemiologic, clinical, and laboratory characteristics of autoimmune hemolytic anemia (AIHA) secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or vaccination. Methods: We conducted a systematic review using standardized keyword search to identify all reports of SARS-CoV-2 infection or vaccination and AIHA across PubMed, Web of Science, Scopus, and Google Scholar through September 24, 2021. Results: Fifty patients (mean [SD] age, 50.8 [21.6] years) diagnosed with coronavirus disease 2019 (COVID-19) and AIHA were identified. AIHA subtypes and number of patients were as follows: cold AIHA (n = 18), warm AIHA (n = 14), mixed-type AIHA (n = 3), direct antiglobulin test (DAT)–negative AIHA (n = 1), DAT-negative Evans syndrome (n = 1), Evans syndrome (n = 3), and subtype not reported (n = 10). Mean (SD) hemoglobin at AIHA diagnosis was 6.5 [2.8] g/dL (95% confidence interval, 5.7-7.3 g/dL). Median time from COVID-19 symptom onset to AIHA diagnosis was 7 days. In total, 19% (8/42) of patients with COVID-19–associated AIHA with reported outcomes were deceased. Four patients (mean [SD] age, 73.5 [16.9] years) developed AIHA following SARS-CoV-2 vaccination: Pfizer-BioNTech BNT162b2 vaccine (n = 2); Moderna mRNA-1273 vaccine (n = 1); undisclosed mRNA vaccine (n = 1). AIHA occurred after 1 dose in 3 patients (median, 5 days). Conclusions: SARS-CoV-2 infection and vaccination are associated with multiple AIHA subtypes, beginning approximately 7 days after infectious symptoms and 5 days after vaccination.

2 June 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
JJJeremy W. Jacobs
Jeremy W. Jacobs
CVCristina A. Figueroa Villalba
Cristina A. Figueroa Villalba
GBGarrett S. Booth
Garrett S. Booth
JWJennifer S. Woo
Jennifer S. Woo
LSLaura D. Stephens
Laura D. Stephens
BABrian D Adkins
Brian D Adkins
Paroxysmal cold hemoglobinuria (PCH) is a rare autoimmune hemolytic anemia often overlooked as a potential etiology of hemolysis and is challenging to diagnose because of the complicated testing methods required. We performed a systematic review of all reported cases to better assess the clinical, immunohematologic, and therapeutic characteristics of PCH. We systematically analyzed PubMed, Medline, and EMBASE to identify all cases of PCH confirmed by Donath-Landsteiner (DL) testing. Three authors independently screened articles for inclusion, and systematically extracted epidemiologic, clinical, laboratory, treatment, and outcomes data. Discrepancies were adjudicated by a fourth author. We identified 230 cases, with median presentation hemoglobin of 6.5 g/dL and nadir of 5.5 g/dL. The most common direct antiglobulin test (DAT) result was the presence of complement and absence of immunoglobulin G (IgG) bound to red blood cells, although other findings were observed in one-third of cases. DL antibody class and specificity were reported for 71 patients, of which 83.1% were IgG anti-P. The use of corticosteroids is common, although we found no significant difference in the length of hospitalization for patients with and without steroid therapy. Recent reports have highlighted the use of complement inhibitors. Among patients with follow-up, 99% (213 of 216) were alive at the time of reporting. To our knowledge, this represents the largest compilation of PCH cases to date. We discovered that contemporary PCH most commonly occurs in children with a preceding viral infection, corticosteroid use is frequent (but potentially ineffective), and DAT results are more disparate than traditionally reported.

26 September 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
JJJeremy W. Jacobs
Jeremy W. Jacobs
IBImelda Bates
Imelda Bates
BMBridon M’bAya
Bridon M’bAya
QEQuentin Eichbaum
Quentin Eichbaum
VLVernon Louw
Vernon Louw
EBEvan M. Bloch
Evan M. Bloch

25 April 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
JJJeremy W. Jacobs
Jeremy W. Jacobs
MDMarlon Diaz
Marlon Diaz
DSDory E. Arevalo Salazar
Dory E. Arevalo Salazar
ATAlbert Tang
Albert Tang
LSLaura D. Stephens
Laura D. Stephens
BABrian D Adkins
Brian D Adkins

20 October 2021 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
JJJeremy W. Jacobs
Jeremy W. Jacobs
GBGarrett S. Booth
Garrett S. Booth